Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
AmnioExcel is a human amniotic membrane allograft (HAMA) derived from the innermost layer of the human placenta. It is processed to maintain the native extracellular matrix (ECM) and endogenous biological factors, including growth factors and cytokines, which are essential for tissue repair and regeneration. AmnioExcel functions as a biological scaffold that facilitates cellular recruitment, migration, and proliferation while modulating inflammation in hard-to-heal wounds. Originally developed by Advanced BioHealing and later acquired by Shire, the product is currently part of the Integra LifeSciences portfolio. It is primarily indicated for the treatment of chronic wounds such as diabetic foot ulcers (DFUs) and venous leg ulcers (VLUs), as well as burns.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on AmnioExcel.